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We appreciate the letter submitted by Dr Burtey and
co-workers in response to our recent report ‘Overexpression
of innate immune response genes in a model of recessive
polycystic kidney disease’.1 As noted in their letter,2 these
investigators observed that, similar to our observations in
the cpk mouse model, genes encoding multiple innate
immune factors, including complement system compo-
nents, were overexpressed in Han:SPRD-Cy rat kidneys.
Furthermore, in reviewing the table in their letter, we note
additional gene expression similarities between these two
models. For example, in cpk kidneys, we also observed
increased expression of Adamts1, Ctsd, Ctsk, Hmox1, Lyz
(under alias Lzp-s), Mmp14, and Vim. In addition, among
the genes overexpressed in Han:SPRD-Cy kidneys, we have
also observed increased expression of F3, Lgals3, Mal, and
Runx1 in cpk kidneys (data not shown in our original
report). These significant parallels in gene expression
profiles indicate that similar immune response pathways
are activated in kidneys from two phenotypically distinct
rodent models, suggesting that this perturbation may be a
common signature of polycystic kidney disease.
1. Mrug M, Zhou J, Woo Y et al. Overexpression of innate immune response
genes in a model of recessive polycystic kidney disease. Kidney Int 2008;
73: 63–76.
2. Burtey S, Riera M, Fontes M. Overexpression of complement components
genes in Han:SPRD rats a model of polycystic kidney disease. Kidney Int
2007 (in press).
M Mrug1, J Zhou1, Y Woo2, X Cui1,3, AJ Szalai1,4, J Novak4,
GA Churchill2 and LM Guay-Woodford1,5,6
1Department of Medicine, Division of Genetic and Translational Medicine,
The University of Alabama at Birmingham, Birmingham, Alabama, USA; 2The
Jackson Laboratory, Bar Harbor, Maine, USA; 3Department of Biostatistics,
The University of Alabama at Birmingham, Birmingham, Alabama, USA;
4Department of Microbiology, The University of Alabama at Birmingham,
Birmingham, Alabama, USA; 5Department of Genetics, The University of
Alabama at Birmingham, Birmingham, Alabama, USA and 6Department
of Pediatrics, The University of Alabama at Birmingham, Birmingham,
Alabama, USA
Correspondence: M Mrug, Department of Medicine, Division of Genetic and
Translational Medicine, University of Alabama at Birmingham, 752 Kaul
Human Genetics Building, 720 20th Street South, Birmingham, Alabama
35294, USA. E-mail: mmrug@uab.edu or LM Guay-Woodford, Department
of Medicine, Division of Genetic and Translational Medicine, University of
Alabama at Birmingham, 740 Kaul Human Genetics Building, 720 20th Street
South, Birmingham, Alabama 35294, USA. E-mail: lgw@uab.edu
Need for a more realistic cut-off
GFR value to define chronic renal
failure
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To the Editor: We read with interest the article titled
‘Age- and gender-specific reference values of estimated GFR
in Caucasians: the Nijmegen Biomedical Study.’ by Wetzels
et al.,1 and the commentary by Poggio et al.2 titled ‘Can we
do better than a single estimated GFR threshold when
screening for chronic kidney disease?’ published in the
September 2007 issue. We have performed a similar work in
Indian population where we have measured glomerular
filtration rate (GFR) in 610 healthy adults and demonstrated
a mean GFR of 81.4 ml min1 compared with 83–85 ml min1
reported by Wetzels et al.1,3
The definition of decreased GFR relies on an under-
standing of the ‘normal’ GFR range. The Kidney Disease
Outcome Quality Initiative guideline accepts normal GFR as
120 ml min1 and a 50% reduction in GFR (o60 ml min1)
constitutes chronic renal failure (CRF).4 It is universally
accepted that GFR declines relentlessly with age; however,
Kidney Disease Outcome Quality Initiative guideline assumes
that GFR is stable between 18 and 70 years. This assumption
allows a single cut-off GFR value for CRF. However, as has
been demonstrated by Wetzels et al., a 60 ml min1 cut-off
tends to over-diagnose CRF. This problem gets accentuated in
India, where normal GFR is itself lower by 2530%. GFR of
a 20-year-old Indian ranges from 89 to 109 ml min1 and
a 50% reduction from normal translates into 45 ml min1.
We agree with Wetzels et al. that GFR of 60 ml min1 cannot
be used to define CRF. Consideration should be given to
reduce the cut-off value for defining CRF, and we believe
45 ml min1 is more realistic in the Indian population.
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